COMPARE · Data as of August 21, 2026

CNC vs PGNY

Verdict: Side-by-side breakdown using the Bull Rankings model. CNC scored 57.6, PGNY scored 65.0 — PGNY leads.
Compare another set
CNC
Centene Corporation
Healthcare Plans · Quality-Growth
57.6
$65.02 · $32.1B
fundamentals as of
Score gap
7.4
PGNY leads
PGNY
Progyny, Inc.
Healthcare Plans · Quality-Growth
65
$25.65 · $2.0B
fundamentals as of
  • Fastest growthCNC+19.4%
  • Strongest balance sheetPGNY0.05
  • Highest qualityPGNY85 / 100
  • Largest discount to fair valueCNC-77%
THE BULL RANKINGS SCORECARD57.6/ 100 · BULL SCOREPEER MEDIANQUALITY27.1GROWTH86.0VALUE81.9
THE BULL RANKINGS SCORECARD65.0/ 100 · BULL SCOREPEER MEDIANQUALITY85.2GROWTH52.7VALUE61.1
CNCPGNYQuality27.185.2Growth86.052.7Value81.961.1
FCFCNC$9.0bPGNY$178m
RevCNC+19.4%PGNY+5.5%
D/ECNC0.71PGNY0.05
PEGCNC0.88PGNY2.56
CNC
stronger →← stronger
PGNY
27
Qualityreturns · margins · balance sheet
85
86
Growthrevenue & earnings expansion
53
82
Valuevaluation vs sector peers
61
CNC is stronger on 2 of 3 pillars.
CNC
PGNY
$9.0bB+
FCF
$178mC
+19.4%B+
Rev
+5.5%C+
0.71C+
D/E
0.05A-
0.2xA
P/S
0.88B+
PEG
2.56C
P/E
28.2xB
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
CNC
PGNY
77% below
Price vs fair valuelower is cheaper
36% below
decline
Growth the price implies10-yr FCF · lower = less priced in
~-4%/yr
+300%
1-yr DCF upside
+42%
+330%
5-yr DCF upside
+57%
+377%
10-yr DCF upside
+82%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
CNC
No notable signals flagged.
PGNY
Why this score
  • Buying back stock
  • Durable high returns
CNCCentene Corporation
Healthcare Plans · $65.02 · beta 1.10
Why now
Healthcare Plans · market cap $32.1b. 6% off the 52-week high of $69.36. Revenue growing +19%, comfortably above the S&P median. PEG 0.88 — paying under fair value for the growth rate. 18 sell-side analysts rate this a Buy with a mean 1-yr target of $71.67 (implying +10% upside).
Moat
Turnaround / out-of-favor name — GAAP-unprofitable for now, so the durability case is forward-looking: it rests on a recovery (margin normalization, a cyclical upturn or restructuring) or an un-monetized asset (IP / network effects / first-mover position) rather than on current reported results.
Risk
Currently unprofitable (margin -2.8%) — path to GAAP profitability is the core thesis risk. ROE -20% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
PGNYProgyny, Inc.
Healthcare Plans · $25.65 · beta 1.02
Why now
Healthcare Plans · market cap $2.0b. Down 22% from 52-week high of $33.06 — deep drawdown territory. 12 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $34.00 (implying +33% upside).
Moat
ROE 17% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong.
Risk
Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.

Where CNC and PGNY diverge

On the headline score the gap is 7.4 points in favor of PGNY. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.

Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.